Presentation is loading. Please wait.

Presentation is loading. Please wait.

Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the.

Published byPaul Allison Modified over 9 years ago

Similar presentations

Presentation on theme: "Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the."— Presentation transcript:

1 Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution N. Fabbri, G. Bacci, S. Ferrari, A. Longhi, D. Donati, M. Manfrini, E. Barbieri, M. Mercuri, F. Bertoni Department of Musculoskeletal Oncology Istituto Ortopedico Rizzoli, Bologna, Italy Department of Musculoskeletal Oncology Istituto Ortopedico Rizzoli, Bologna, Italy

2 Surgery vs Radiation Therapy in Ewing’s Sarcoma Ewing’s Sarcoma in 21st Century. Outcome considerably improved from 70’s. Multiagent chemotherapy fundamental. Improved LC and survival with surgery. Retrospective data, bias Rxt worse cases

3 Surgery vs Radiation Therapy in Ewing’s Sarcoma Surgery vs Rxt: Literature. Pritchard et al., Cancer, 1975 - 229 pts, pre-Cht experience (1912-1968) - Extremity & Surgery in survivors > 5 yrs. Rosen et al., Cancer, 1978 - 20 pts, multimodal management since 1970 - 13 pts, T6 + T2 & Surgery +/- Rxt, 85% at 3 yrs. Bacci et al., JBJS-B, 1978 - 37 pts, multimodal management since 1972 - Surgery + Cht 90% vs Rxt + Cht 55% at 2 yrs

4 Surgery vs Radiation Therapy in Ewing’s Sarcoma F, 17 - Ewing’s sarcoma: pre-chemotherapy

5 Surgery vs Radiation Therapy in Ewing’s Sarcoma F, 17 - Ewing’s sarcoma: post-chemotherapy

6 Surgery vs Radiation Therapy in Ewing’s Sarcoma 3 yr FU

7 Disease-Free Survival 72% (91-97) 78% (91-97) 43% (83-87) Cum. Survival Months 50 100 150 200 250 0 0 0.2 0.4 0.6 0.8 1 1 0 0 Surgery vs Radiation Therapy in Ewing’s Sarcoma

8 Surgery vs Rxt: Multicentric Studies. Jurgens et al., Cancer, 1988 (CESS). Burgert et al., J Clin Oncol, 1990 (IESS). Oberlin et al., J Clin Oncol, 1992 (FSPO). Craft et al., Eur J Cancer, 1997 (UKCCSG). Grier et al., N Eng J Med, 2003 (CCG-POG) More surgery, trend towards better survival

9 Surgery vs Radiation Therapy in Ewing’s Sarcoma Surgery vs Rxt: Monocentric Studies. Wilkins et al., Cancer, 1986 (Mayo Clinic). Ozaki et al., Cancer, 1996 (Munster). Bacci et al., J Clin Oncol, 2000 (Rizzoli). Sluga et al., CORR, 2001 (Vienna). Bacci et al., JBJS-B, 2003 (Rizzoli) Surgery better survival, statistical evidence

10 Surgery vs Radiation Therapy in Ewing’s Sarcoma Controversies in Local Management 1) Surgery vs Rxt to survival 2) Margin and local control to survival 3) Postoperative Rxt after inadequate margin 4) Histol. response and margin to local control

11 Surgery vs Radiation Therapy in Ewing’s Sarcoma Materials and Methods. Rizzoli series 1979-1999, retrospective. 512 pts. with nonmetastatic ES of bone. 4 different adjuvant (1) and neoadjuvant (3) studies. Surgery 196, Surgery+Rxt (45 Gy) 139: 335 pts. Full dose Rxt (61 Gy): 177 pts

12 Surgery vs Radiation Therapy in Ewing’s Sarcoma Materials and Methods. Evolving strategies for local control. Surgery initially only if no reconstruction needed. Postop Rxt individual basis (no risk, inad. margin). Full dose Rxt: nonoperable, refuse amputation. Initial target: 5 cm axial and 2 cm radial margins 45 Gy target volume + 16 Gy central boost

13 Surgery vs Radiation Therapy in Ewing’s Sarcoma. Evaluation of Surgical Margin Enneking et al., Chir Organi Mov, 1990. Assessment of Histologic Response Picci et al., J Clin Oncol, 1993 - Grade I macroscopic viable tumor PR - Grade II microscopic viable tumor - Grade III no viable tumor Materials and Methods GR

14 Surgery vs Radiation Therapy in Ewing’s Sarcoma Materials and Methods. Pts traced from diagnosis to relapse or last FU. Local management and margin to EFS and LC. Cumulative EFS and LC by Kaplan-Meier. Statistics by chi-square test with Fisher’s correction. Cox regression multiv. analysis in factors significant at univ. analysis in neoadj. pts (90%)

15 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Population. M 328 (64%), F 184 (36%); median age 17. Extremities 326 (64%), Axial 186 (36%). Femur 122, Tibia 80, Fibula 53, Humerus 44. Pelvis-Sacrum 109, Spine 20

16 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Population. LDH: normal 68%, elevated 32% (499 pts). Volume: 150 ml 43% (454 pts). Cht: adjuvant 58 (11%), neoadjuv. 454 (89%)

17 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Overall Treatment. Surgery/+Rxt 335 (65%); Rxt 177 (35%). Rxt 51% 1979-82 to 26% 1991-99 p <.0004. FU 5-22 years, median FU 12 years. EFS 271 pts (53%), Relapse 231 (45%) - 10 pts (2%) died of tmx complic. or 2nd tumor. 5 yr EFS 58%, 5 yr OS 66%

18 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Patient / Tumor Variables. Gender: M 54% F 66% p <.005. Age: 14 yrs 56% p <.002. Site: Extremity 62% Axial 51% p <.02. Serum LDH: N 68% E 37% p <.001. Volume: 150 ml 54% p <.01

19 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Treatment Variables. Local Tmx: Surgery 68% Rxt 47% p <.0003 Surgery + Rxt 58% ns. Surgery vs Rxt: Extremity p <.03 Axial ns. Margin: Adeq. 69% Inad. 47% p <.0003 Inadequate Surgery + Rxt ns

20 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Treatment Variables. Response: GR 77% PR 38% p <.0001 GR: Grade II vs Grade III ns. Cht: Adjuvant 57% Neoadjuvant 58% ns

21 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Treatment and LR. LR: Surgery 9% Rxt 19% p<.04. Surgery vs Rxt: Extremity p<.06 Axial ns. LR rate: Extremity 9% Axial 19% p<.003

22 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Margin, LR and Response. LR rate: Adeq. 7% Inadeq. 19% p<.001 Inadequate Surgery + Rxt ns. Ad. Margin: Extremity 88% Axial 36% p<.001. GR (II+III): Adeq 79% Inadeq 67% p<.001. LR rate: GR 6% PR 21% p<.0002

23 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Margin, LR and Response. LR, Margin and Response: - Adequate + G I 14% - Adequate + G II / III 5% - Inadequate + G I 22% - Inadequate + G II / III 13% p<.005

24 Surgery vs Radiation Therapy in Ewing’s Sarcoma Results - Multivariate Analysis. Histologic Response p<.0001. Local Management p<.01. Surgical Margin p<.04. Serum LDH p<.0001. Tumor Volume p<.0004. Age p<.003

25 Surgery vs Radiation Therapy in Ewing’s Sarcoma Conclusions. Overall better results with Surgery than Rxt. Significant in extremities, ns in axial. Reinforced role for Surgery in local management 1) Surgery vs Radiation Therapy to survival

26 Surgery vs Radiation Therapy in Ewing’s Sarcoma Conclusions. Reinforced importance for Surgical Margin. Adequate Margin always needed. Impact on Local Recurrence and Survival 2) Surgical margin, local control and survival

27 Surgery vs Radiation Therapy in Ewing’s Sarcoma Conclusions. No benefit from low-dose (45 Gy) postop Rxt. Different strategy needed (60 Gy, IBRT, IORT?) 3) Postoperative Rxt after inadequate margin

28 Surgery vs Radiation Therapy in Ewing’s Sarcoma Conclusions. Correlates with Local Recurrence and Survival. Good Response does not protect from LR. Always aiming for Adequate Margin 4) Histologic response and optimal margin

29 CTOS 2006, Venice, Italy November 2-4, 2006

Download ppt "Surgery vs Radiation Therapy in Ewing’s Sarcoma the Extremities: Experience of a Single Institution Surgery vs Radiation Therapy in Ewing’s Sarcoma the."

Similar presentations

Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.

Danny Indelicato, MD CTOS 2012 Ewing Sarcoma of the Axial Skeleton: Early Outcomes from the University of Florida Proton Therapy Program.
Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.

Evaluation of Femur Fracture Risk in Soft-Tissue Sarcoma of the Thigh Treated with Intensity- Modulated Radiation Therapy (IMRT) Michael R. Folkert, MD.
Value of local treatment in extrapulmonary metastatic Ewing sarcoma

Value of local treatment in extrapulmonary metastatic Ewing sarcoma
Chondrosarcoma of the Pelvis Prognostic Factors and Survival Analysis at 10-20 Years Matthew J. Seidel, MD Patrick P. Lin, MD Valerae O. Lewis, MD Christopher.

Chondrosarcoma of the Pelvis Prognostic Factors and Survival Analysis at Years Matthew J. Seidel, MD Patrick P. Lin, MD Valerae O. Lewis, MD Christopher.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Clinicopathologic Characteristics and Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery Emily.

Clinicopathologic Characteristics and Predictors of Outcomes in Patients with Primary Retroperitoneal Dedifferentiated Liposarcoma Undergoing Surgery Emily.
GOS Paediatric Sarcoma Surgery Combined UCL Sarcoma Service GOS Oncology and London Bone and Soft Tissue Tumour Service UCLH.

GOS Paediatric Sarcoma Surgery Combined UCL Sarcoma Service GOS Oncology and London Bone and Soft Tissue Tumour Service UCLH.
IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.

IMRT vs. BRACHYTHERAPY FOR SOFT TISSUE SARCOMA. EXTERNAL RT IN STS NCI Trial (Yang JC et al, JCO 1998) Extremity / Superficial Trunk STS (n=141) LSS Alone.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.

Synovial sarcoma- which patients don’t need adjuvant treatment? Khan M, Rankin KS, Beckingsale TB, Todd R, Gerrand CH North of England Bone and Soft Tissue.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.

BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.

Pier Luigi Filosso, MD University of Torino, Department of Thoracic Surgery The Impact of Adjuvant Chemotherapy in Pulmonary Large Cell Neuroendocrine.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.

Thomas F. DeLaney MD, Aashish D. Bhatt MD, Alex Jacobson BS, Richard Y. Lee MD, PhD, Christine Giraud BS, Joseph H. Schwab MD, MS, Francis J. Hornicek.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;

PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.

Pulmonary Metastasis From Osteosarcoma Multi-factorial analysis of survival at first lung involvement Ali Aljubran, Martin Blackstein for the University.
Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Outcome Following Limb Salvage Surgery and External Beam Radiotherapy for High Grade Soft Tissue Sarcomas of the Groin and Axilla Rapin Phimolsarnti M.D.

Similar presentations

Ads by Google